These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 26967759)

  • 1. Half-life extended biotherapeutics.
    Kontermann RE
    Expert Opin Biol Ther; 2016 Jul; 16(7):903-15. PubMed ID: 26967759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular recycling-driven in vivo half-life extension using recombinant albumin fusions tuned for neonatal Fc receptor (FcRn) engagement.
    Larsen MT; Rawsthorne H; Schelde KK; Dagnæs-Hansen F; Cameron J; Howard KA
    J Control Release; 2018 Oct; 287():132-141. PubMed ID: 30016735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
    Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
    J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of protein aggregates on characterization of FcRn binding of Fc-fusion therapeutics.
    Bajardi-Taccioli A; Blum A; Xu C; Sosic Z; Bergelson S; Feschenko M
    Mol Immunol; 2015 Oct; 67(2 Pt B):616-24. PubMed ID: 26254986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo pharmacokinetic enhancement of monomeric Fc and monovalent bispecific designs through structural guidance.
    Shan L; Dyk NV; Haskins N; Cook KM; Rosenthal KL; Mazor R; Dragulin-Otto S; Jiang Y; Wu H; Dall'Acqua WF; Borrok MJ; Damschroder MM; Oganesyan V
    Commun Biol; 2021 Sep; 4(1):1048. PubMed ID: 34497355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering a monomeric Fc domain modality by N-glycosylation for the half-life extension of biotherapeutics.
    Ishino T; Wang M; Mosyak L; Tam A; Duan W; Svenson K; Joyce A; O'Hara DM; Lin L; Somers WS; Kriz R
    J Biol Chem; 2013 Jun; 288(23):16529-16537. PubMed ID: 23615911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Albumin and its application in drug delivery.
    Sleep D
    Expert Opin Drug Deliv; 2015 May; 12(5):793-812. PubMed ID: 25518870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics.
    Dumont JA; Low SC; Peters RT; Bitonti AJ
    BioDrugs; 2006; 20(3):151-60. PubMed ID: 16724863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting.
    Meyer S; Nederend M; Jansen JH; Reiding KR; Jacobino SR; Meeldijk J; Bovenschen N; Wuhrer M; Valerius T; Ubink R; Boross P; Rouwendal G; Leusen JH
    MAbs; 2016; 8(1):87-98. PubMed ID: 26466856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein.
    Seijsing J; Lindborg M; Höidén-Guthenberg I; Bönisch H; Guneriusson E; Frejd FY; Abrahmsén L; Ekblad C; Löfblom J; Uhlén M; Gräslund T
    Proc Natl Acad Sci U S A; 2014 Dec; 111(48):17110-5. PubMed ID: 25406323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.
    Wang Y; Tian Z; Thirumalai D; Zhang X
    J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of Peptide-Fc fusion proteins.
    Wu B; Sun YN
    J Pharm Sci; 2014 Jan; 103(1):53-64. PubMed ID: 24285510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative methods for developing Fc mutants with extended half-lives.
    Kamei DT; Lao BJ; Ricci MS; Deshpande R; Xu H; Tidor B; Lauffenburger DA
    Biotechnol Bioeng; 2005 Dec; 92(6):748-60. PubMed ID: 16136591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single chain Fc-dimer-human growth hormone fusion protein for improved drug delivery.
    Zhou L; Wang HY; Tong S; Okamoto CT; Shen WC; Zaro JL
    Biomaterials; 2017 Feb; 117():24-31. PubMed ID: 27923197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineered FcRn Binding Fusion Peptides Significantly Enhance the Half-Life of a Fab Domain in Cynomolgus Monkeys.
    Datta-Mannan A; Boyles J; Huang L; Jin ZY; Peariso A; Murphy AT; Ellis B; Douglass N; Norouziyan-Cooper F; Witcher DR
    Biotechnol J; 2019 Mar; 14(3):e1800007. PubMed ID: 29802766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.
    Souders CA; Nelson SC; Wang Y; Crowley AR; Klempner MS; Thomas W
    MAbs; 2015; 7(5):912-21. PubMed ID: 26018774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The versatile MHC class I-related FcRn protects IgG and albumin from degradation: implications for development of new diagnostics and therapeutics.
    Andersen JT; Sandlie I
    Drug Metab Pharmacokinet; 2009; 24(4):318-32. PubMed ID: 19745559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Qualification of a homogeneous cell-based neonatal Fc receptor (FcRn) binding assay and its application to studies on Fc functionality of IgG-based therapeutics.
    Mathur A; Arora T; Liu L; Crouse-Zeineddini J; Mukku V
    J Immunol Methods; 2013 Apr; 390(1-2):81-91. PubMed ID: 23384837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of new models for the analysis of Fc-FcRn interactions.
    Gurbaxani BM; Morrison SL
    Mol Immunol; 2006 Mar; 43(9):1379-89. PubMed ID: 16183124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fc engineering: serum half-life modulation through FcRn binding.
    Olafsen T
    Methods Mol Biol; 2012; 907():537-56. PubMed ID: 22907373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.